Novartis Withdraws EU Application for Pluvicto Label Expansion

Novartis (NVS) announced on Friday that it has withdrawn its application to expand the marketing label for Pluvicto in the European Union. The radiotherapy treatment, specifically used for metastatic castration-resistant prostate cancer (mCRPC), was being positioned for a broader patient population to increase its clinical utility. The withdrawal comes after the company received regulatory feedback concerning its type II variation application. In the pharmaceutical industry, a type II variation is typically utilized to update existing marketing authorizations to include new indications, changes in dosage, or other significant modifications to the product's approved use. While Pluvicto remains a cornerstone of the Novartis oncology portfolio, the inability to expand its EU label in the immediate term may limit the drug's growth trajectory and market penetration within the European region. The company did not provide specific details regarding the nature of the regulatory feedback that led to the decision. From a market perspective, regulatory setbacks for high-profile drugs often act as short-term headwinds for revenue projections. Investors will likely monitor whether Novartis intends to address the regulatory concerns and resubmit the application or if this represents a strategic pivot in the drug's deployment in Europe.